- 1 A distinct metabolic profile associated with a fatal outcome in COVID-19 patients during early
- 2 epidemic in Italy

- 4 Elisa Saccon<sup>1</sup>, Alessandra Bandera<sup>2,3,4</sup>, Mariarita Sciumè<sup>5</sup>, Flora Mikeloff<sup>1</sup>, Abid Ali Lashari<sup>6</sup>, Stefano
- 5 Aliberti<sup>3,7</sup>, Michael Sachs<sup>6</sup>, Filippo Billi<sup>8</sup>, Francesco Blasi<sup>3,7</sup>, Erin Gabriel<sup>6</sup>, Giorgio Costantino<sup>9,10</sup>,
- 6 Pasquale De Roberto<sup>5</sup>, Shuba Krishnan<sup>1</sup>, Andrea Gori<sup>2,3,4</sup>, Flora Peyvandi<sup>3,11</sup>, Luigia Scudeller<sup>12</sup>,
- 7 Christian L. Lorson<sup>13,14</sup>, Luca Valenti<sup>3,15</sup>, Kamal Singh<sup>13,14</sup>, Luca Baldini<sup>5,16</sup>, Nicola Stefano
- 8 Fracchiolla<sup>5\*</sup> on behalf of the "COVID-19 NETWORK" working group<sup>#</sup>, Ujjwal Neogi<sup>1,13\*</sup>
- 10 <sup>1</sup>Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institute,
- 11 Stockholm, Sweden
- <sup>2</sup>Infectious Diseases Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
- <sup>3</sup>Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
- <sup>4</sup>Centre for Multidisciplinary Research in Health Science (MACH), University of Milan, Milan, Italy
- <sup>5</sup>Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
- 16 Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden
- <sup>7</sup>Internal Medicine Department, Respiratory Unit and Cystic Fibrosis Adult Center, Fondazione
- 18 IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
- 19 \*Acute Medical Unit, Deptartment of Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore
- 20 Policlinico, Milan, Italy
- <sup>9</sup>Department of Anesthesia, Critical Care and Emergency, Fondazione IRCCS Ca' Granda Ospedale
- 22 Maggiore Policlinico, Milan, Italy
- 23 <sup>10</sup>Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.
- 24 <sup>11</sup>Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Ca' Granda Ospedale
- 25 Maggiore Policlinico, Milan, Italy
- 26 12Clinical Trials Team, Scientific Direction, Fondazione IRCCS Ca' Granda Ospedale Maggiore
- 27 Policlinico, Milan, Italy
- 28 <sup>13</sup>Bond Life Sciences Center, University of Missouri, Columbia, USA

29 <sup>14</sup>Department of Veterinary Pathobiology, University of Missouri, Columbia, USA 30 <sup>15</sup>Precision Medicine Unit, Department of Transfusion Medicine and Hematology, Fondazione IRCCS 31 Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy <sup>16</sup>Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy 32 33 34 \* Equal contribution 35 <sup>#</sup> All the names are reported in the acknowledgments section 36 37 **Keywords:** COVID-19, metabolomics, fatal outcome, Italy, predictive biomarkers 38 39 Corresponding authors: 40 Nicola Fracchiolla (nicola.fracchiolla@policlinico.mi.it) and Ujjwal Neogi (ujjwal.neogi@ki.se) 41

42 **Abstract** 43 Leveraging the unique biological resource based upon the initial COVID-19 patients in Policlinico di 44 Milano (Italy), our study provides the first metabolic profile associated with a fatal outcome. The 45 identification of potential predictive biomarkers offers a vital opportunity to employ metabolomics in 46 a clinical setting as diagnostic tool of disease prognosis upon hospital admission. 47 48 Introduction 49 As of February 2021, more than 100 million cases of coronavirus disease 2019 (COVID-19), caused 50 by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, had been confirmed globally, with more than 2 million related deaths (https://covid19.who.int/). Although most 52 individuals remain asymptomatic or display mild symptoms, 15-20% of patients exhibit severe 53 symptoms, specifically respiratory distress, often requiring mechanical ventilation or/and intensive 54 care (ICU) admission [1], with a mortality rate after ICU admission estimated around 40% [2]. 55 Multiple studies have identified profound underlying conditions that demonstrate increased 56 susceptibility to a more severe prognosis and a higher risk of fatality, including the male gender, old 57 age [3], or certain underlying medical conditions, such as hypertension, cardiovascular diseases, 58 diabetes or obesity [4]. Additionally, patients infected with SARS-CoV-2 present metabolic 59 dysregulation, possibly due to immune-triggered inflammation or other changes in the host 60 physiology, and that these alterations often reflect the disease severity [1,5,6]. For instance, levels of particular amino acids positively correlated with severe COVID-19 cases [1,7]. Moreover, 62 perturbations in energy metabolisms, TCA and urea cycle [6] and lipid metabolism [1,8] are correlated 63 to disease prognosis. Thus, it is essential to assemble a complete metabolic signature correlated to 64 disease severity to identify a set of biomarkers strongly associated with the patient outcome, with the 65 final goal of employing them for diagnostics and therapeutic purposes. 66 Our study retrospectively analyzes the metabolome profile of 75 COVID-19 patients with moderate and severe symptoms admitted to Policlinico di Milano (Lombardy region, Italy) following SARS-68 CoV-2 infection between March and April 2020. Italy was the first Western country to experience COVID-19 disease, and the Lombardy region was the epicenter of the Italian COVID-19 pandemic.

51

61

67

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

This cohort shows a higher mortality rate compared to others; therefore, it represents a unique opportunity to investigate the underlying metabolic profiles of the first COVID-19 patients in Italy and to identify potential predictive biomarkers. Methods Plasma samples from 75 COVID19 patients were collected at the moment of admission to Policlinico di Milano (Italy) from March to April 2020 and SARS-CoV-2 positivity was confirmed by PCR (Ethical Clearance No. 462-2020-bis). Patients were initially classified based on the type of ventilation received: Nasal cannula (n=25) and VentMask (n=25) (moderate cases) or CPAP (n=25) (severe cases). Plasma untargeted metabolomics was performed by Global Metabolomics (HD4) in Metabolon, (USA) as previously described [9]. The metabolomics method is ISO 9001:2015 certified and the lab is accredited by the College of American Pathologist (CAP), USA. Clinical data was collected from the registries. Logistic regression was used to model associations of each biomarker with COVID-19-related inhospital mortality adjusting for age, gender, and body mass index (BMI). As BMI was missing for many patients, multivariate imputation by chained equations (MICE) was used (via the MICE Rpackage) to impute BMI. Imputation was done in two stages, first including no biomarkers, and then including those biomarkers that were found to be significant under the original imputation. The resulting pooled estimates and inference were obtained using Rubin's rules. P-values were not adjusted in this analysis. Metabolomics data were log2 transformed and plotted using histograms with normal distribution superimposed. R package LIMMA was applied for differential abundance analysis between different mask types (Nasal cannula/VentMask/CPAP), outcome (survivors/non-survivors), and severity (moderate/severe). Adjustment for multiple testing was assessed using false discovery rate (FDR) <0.05. Heatmap was built using the R package ComplexHeatmap. Uniform Manifold Approximation and Projection (UMAP) representations were done using the R package UMAP. Metabolites with variance equal to zero were removed and positive significant pairwise correlations after Bonferonni

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

correction (Spearman, adjusted p<0.00001) were used for association analysis. The strength of the connections was evaluated by plotting distribution of correlation coefficients in a graphical network using igraph (https://igraph.org/python/). The network was compared to a random network with similar dimensions to validate the structure of the network to be not due to chance. Community detection was performed using Leiden algorithm (https://leidenalg.readthedocs.io/en/stable/index.html). For each community large enough (n>30), metabolite set enrichment analysis (MSEA) with KEGG and Metabolon terms via the Python module gseapy was performed. The average degree and clustering coefficient were calculated for each community. The final network was build using Cytoscape and biomarkers that were significantly associated with death were highlighted. **Results and discussion** Among the 75 patients enrolled in this study, 24% (18/75) succumbed to death in the hospital (Supplementary Table 1) and a significantly higher rate of fatal outcomes was observed for severe cases compared to moderate cases (p=0.0218, Chi-square test). Among patients who died, comorbidities were nearly universally observed (94%, 17/18). Underlying conditions, like hypertension, were recorded for 46% (26/57) of the survivors and 50% (9/18) of the non-survivors, while cardiovascular diseases were significantly more common in non-survivors (p=0.0320, Fisher's exact test) compared to survivors. Among the serological markers, lactate was significantly higher (p<0.0001, Mann-Whitney test) in non-survivors compared to survivors, confirming its tight link to disease severity [10]. In a logistic regression analysis (adjusted to age, gender, and BMI), 35 metabolites, among the >1000 tested, were significantly associated with COVID-19 mortality (p<0.05, unadjusted), among which 10 biomarkers were significant at the unadjusted 0.025 level (Figure 1A). Interestingly, cyclic adenosine monophosphate (cAMP) is significantly increased in non-survivors compared to survivors (OR: 7.4 95% CI 1.5 - 37), cAMP is a well-known intracellular messenger that functions as a regulator of various cellular activities, including cell growth and differentiation, gene transcription, protein expression, and is intimately involved in mitochondrial dynamics [11]. As cAMP plays a role in

SARS-CoV-2 endocytosis in the initial phases of the infection [12], its involvement in disease progression is worthy of further investigations as a potential biomarker. Using UMAP, we observed that the distribution of the patients in the biomarker enrichment showed a separation between survivors and non-survivors (Figure 1B). No specific pattern or clustering was observed for comorbidities (Fig 1C), the number of comorbidities (Fig 1D), or diabetes (Fig 1E), indicating that these metabolite sets only differentiate related to the clinical outcome. To further understand the patterns of metabolic changes related to COVID-19, we performed a weighted correlation network analysis on the metabolomics dataset, using significant positive correlations (Spearman, adjusted p<0.00001). We identified 10 metabolites communities highly connected in a network of 916 nodes (metabolites) and 11453 edges (Figure 1F). Six predicted biomarkers (out of the 10 previously identified with p<0.025, unadjusted) were highly correlated and were present in the network and belong to the lipid pathways. These metabolites are also known to be associated with peroxisomal fatty acid oxidation disorders (3-hydroxysebacate) [13] or insuline resistance (5-dodecenate (12:1n7), tetradecadienoate (14:2)\* and myristoleate (14:1n5)) [14]. Finally, to further discriminate the subset of metabolites significantly associated with a fatal clinical outcome, we selected all the biomarkers and their first neighbors in the network analysis previously described (238 metabolites). Based on these data, we found a clear clustering of non-survivors in opposition to survivors (Fig 1G). No clustering according to mask type was observed, indicating that the metabolic signature associated with mortality appears to be independent of the oxygen demand at the moment of hospitalization, providing the first identified correlation between a metabolite profile and disease severity in COVID-19 patients. It is important to consider that when this study was planned (March-April 2020), there was little knowledge about the COVID-19. Therefore, several clinical data were missing. Despite that, this is the first set of biomarkers identified from high throughput metabolomics data that are associated with mortality and are not confounded by other preexisting conditions.

## **Conclusions**

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

Our analysis has identified metabolic biomarkers that in our data differentiate between COVID-19 survivors and non-survivors and that may be predictive of death from COVID-19, from the early stage of the epidemic, independently from oxygen demand at the moment of diagnosis. Our results on high throughput metabolomics contribute to a better understanding of COVID-19-related metabolic disruption and may represent a useful starting point for the identification of independent prognostic factors to be employed in the therapeutic practice. **Authors' contribution** U.N. and N.S.F. designed the study. E.S., A.B., M.Sciumè, F.M., A.A.L., S.A., M.Sachs, F.Billi, F.Blasi, E.G., G.C., P.D., S.K., A.G., F.P., L.S. analyzed the data and performed the statistical analyses. E.S., U.N., N.S.F. wrote the paper. U.N. and K.S. acquired the fundings. E.S., C.L., L.V., K.S., L.B., N.S.F., U.N. reviewed and edited the paper. All authors read and approved the final manuscript. **Funding** The study was supported by Swedish Research Council Grants (2017-01330) and Karolinska Institute Stiftelser och Fonder (2020-01554) to U.N and by Office of Research, University of Missouri, Columbia, USA to K.S. E.S. was partially supported by VR (2020-05836). **Declaration of competing interest** C.L.L is co-founder and CSO of Shift Pharmaceuticals. All other authors declare no competing conflicts of interest. Acknowledgments The authors would also like to thank all patients involved in this study, as well as the dedicated medical and research staff who fight against SARS-CoV-2. We also like to acknowledge the work of the "COVID-19 NETWORK" working group: Responsible person: Prof. Silvano Bosari

181 Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy 182 Scientific Direction: Silvano Bosari, Luigia Scudeller, Giuliana Fusetti, Laura Rusconi, Silvia 183 Dell'Orto. Transfusion Medicine (Biobank): Daniele Prati, Luca Valenti, Silvia Giovannelli. 184 Infectious Diseases Unit: Andrea Gori, Alessandra Bandera, Antonio Muscatello, Davide Mangioni, 185 Laura Alagna, Giorgio Bozzi, Andrea Lombardi, Riccardo Ungaro, Teresa Itri, Valentina Ferroni, 186 Valeria Pastore, Roberta Massafra, Ilaria Rondolini, Angelo Bianchi Bonomi. Internal Medicine, 187 Hemophilia and Thrombosis Center and Fondazione Luigi Villa: Flora Peyvandi, Roberta Gualtierotti, 188 Barbara Ferrari, Raffaella Rossio, Elisabetta Corona, Nicolò Rampi, Costanza Massimo. Internal 189 Medicine, Immunology and Allergology: Nicola Montano, Barbara Vigone, Chiara Bellocchi, Giulia 190 Coti, Mimma Sternativo. Respiratory Unit and Cystic Fibrosis Adult Center: Francesco Blasi, Stefano 191 Aliberti, Maura Spotti, Edoardo Simonetta, Leonardo Terranova, Francesco Amati, Carmen Miele, 192 Annalisa Vigni. Emergency Medicine: Giorgio Costantino, Monica Solbiati, Ludovico Furlan, Marta 193 Mancarella, Giulia Colombo, Giorgio Colombo. Acute Internal Medicine: Valter Monzani, Angelo 194 Rovellini, Filippo Billi, Christian Folli Internal Medicine: Marina Baldini, Irena Motta. General 195 Medicine and Metabolic Diseases: Anna Fracanzani, Rosa Lombardi. Geriatric Unit: Matteo Cesari, 196 Marco Proietti. Istituto di Ricerche Farmacologiche Mario Negri IRCCS: Alessandro Nobili, Mauro 197 Tettamanti.

198 References 199 [1] Shen B, Yi X, Sun Y, Bi X, Du J, Zhang C, et al. Proteomic and Metabolomic Characterization 200 of COVID-19 Patient Sera. Cell 2020;182:59-72.e15. 201 https://doi.org/10.1016/j.cell.2020.05.032. 202 [2] Armstrong RA, Kane AD, Cook TM. Outcomes from intensive care in patients with COVID-203 19: a systematic review and meta-analysis of observational studies. Anaesthesia 2020;75:1340-204 9. https://doi.org/https://doi.org/10.1111/anae.15201. 205 [3] Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors 206 associated with COVID-19-related death using OpenSAFELY. Nature 2020;584:430-6. 207 https://doi.org/10.1038/s41586-020-2521-4. 208 [4] Zhou Y, Yang Q, Chi J, Dong B, Lv W, Shen L, et al. Comorbidities and the risk of severe or 209 fatal outcomes associated with coronavirus disease 2019: A systematic review and meta-210 analysis. Int J Infect Dis 2020;99:47–56. https://doi.org/10.1016/j.ijid.2020.07.029. 211 [5] Fraser DD, Slessarev M, Martin CM, Daley M, Patel MA, Miller MR, et al. Metabolomics 212 Profiling of Critically Ill Coronavirus Disease 2019 Patients: Identification of Diagnostic and 213 Prognostic Biomarkers. Crit Care Explor 2020;2:e0272-e0272. 214 https://doi.org/10.1097/CCE.0000000000000272. 215 [6] Wu D, Shu T, Yang X, Song J-X, Zhang M, Yao C, et al. Plasma metabolomic and lipidomic 216 alterations associated with COVID-19. Natl Sci Rev 2020;7:1157-68. 217 https://doi.org/10.1093/nsr/nwaa086. 218 [7] Su Y, Chen D, Yuan D, Lausted C, Choi J, Dai CL, et al. Multi-Omics Resolves a Sharp 219 Disease-State Shift between Mild and Moderate COVID-19. Cell 2020;183:1479-1495.e20. 220 https://doi.org/10.1016/j.cell.2020.10.037. 221 [8] Song J-W, Lam SM, Fan X, Cao W-J, Wang S-Y, Tian H, et al. Omics-Driven Systems 222 Interrogation of Metabolic Dysregulation in COVID-19 Pathogenesis. Cell Metab 223 2020;32:188-202.e5. https://doi.org/10.1016/j.cmet.2020.06.016. 224 [9] Sperk M, Mikaeloff F, Svensson-Akusjärvi S, Ponnan SM, Nowak P, Sönnerborg A, et al. 225 Distinct Lipid Profile, Low-Level Inflammation and Increased Antioxidant Defense as a

226 Signature in HIV-1 Elite Control Status. SSRN Electron J 2020. 227 https://doi.org/10.2139/ssrn.3680819. 228 [10] Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in 229 adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol 2020;146:110-8. 230 https://doi.org/10.1016/j.jaci.2020.04.006. 231 [11] Di Benedetto G, Gerbino A, Lefkimmiatis K. Shaping mitochondrial dynamics: The role of 232 cAMP signalling. Biochem Biophys Res Commun 2018;500:65–74. 233 https://doi.org/https://doi.org/10.1016/j.bbrc.2017.05.041. 234 Aslam M, Ladilov Y. Targeting the sAC-Dependent cAMP Pool to Prevent SARS-Cov-2 [12] 235 Infection. Cells 2020;9:1962. https://doi.org/10.3390/cells9091962. 236 [13] Muth A, Mosandl A, Wanders RJA, Nowaczyk MJM, Baric I, Böhles H, et al. Stereoselective 237 analysis of 2-hydroxysebacic acid in urine of patients with Zellweger syndrome and of 238 premature infants fed withmedium-chain triglycerides. J Inherit Metab Dis 2003;26:583–92. 239 https://doi.org/https://doi.org/10.1023/A:1025908216639. 240 Diboun I, Al-Mansoori L, Al-Jaber H, Albagha O, Elrayess MA. Metabolomics of [14] 241 Lean/Overweight Insulin-Resistant Females Reveals Alterations in Steroids and Fatty Acids. J 242 Clin Endocrinol Metab 2021;106:e638–49. https://doi.org/10.1210/clinem/dgaa732. 243 244 245

## Table 1: Characteristics of the study population

	Survivors	Non-survivors	p value
Number	57	18	
Gender			0.1169
- Male (%)	17 (30.4%)	9 (50%)	
- Female (%)	40 (69.4%)	9 (50%)	
Age in years, median (IQR)	62 (52-73.5)	76.5 (68.5-82)	0.0013
BMI, median (IQR)*	26.3 (24.4-29.5)	29.6 (27-32.2)	0.1697
SpO2, median (IQR)*	97 (94.25-98)	95 (89.25-98)	0.0768
pH, median (IQR)*	7.48 (7.45-7.5)	7.49 (7.45-7.53)	0.6672
Lactate, median (IQR)*	0.9 (0.7-1.1)	1.5 (1.1-1.8)	< 0.0001
Comorbidities (%):	38 (66.7%)	17 (94%)	0.0297
- Hypertension	26 (46.4%)	9 (50%)	0.7913
- Diabetes	9 (16%)	3 (16.7%)	NS
- Lung disease	4 (7.1%)	1 (5.6%)	NS
- COPD	4 (7.1%)	2 (11.1%)	0.6257
- Obesity	8 (14.3%)	6 (33%)	0.0867
- Renal disease	4 (7.1%)	3 (16.7%)	0.3481
- Liver disease	1 (1.8%)	1 (5.6%)	0.4249
- Cardiovascular disease	7 (12.5%)	7 (38.9%)	0.0320
- Cerebrovascular disease	2 (3.6%)	0	NS
- Others**	14 (24.6%)	11 (61.1%)	
Number of comorbidities (listed above):			0.0047
- None	19 (33.4%)	1 (5.6%)	
- One	16 (28%)	3 (16.7%)	
- Two	9 (15.8%)	6 (33%)	
- Three or more	13 (22.8%)	8 (44.4%)	
Disease severity§:		. ,	0.0218
- Moderate	42 (73.7%)	8 (44.4%)	
- Severe	15 (26.3%)	10 (55.6%)	

<sup>\*</sup> Calculated from the available data

<sup>\*\*</sup> Gastrointestinal reflux, dyslipidemia, neoplasia, dementia

<sup>§</sup> Based on the masks

Figure 1: 10 metabolites are significantly associated with COVID-19 related in-hospital mortality.

A. All biomarkers that were significant at the 0.05 level, after adjustment of age, gender, and BMI, were included in the plot and order by the value of the odds ratio. Color coding for lower p-values is presented in the legend.

B-E. UMAP visualization of patients' data after selecting the 10 death biomarkers. Patients were labeled for the B. outcome, C. presence of comorbidities, D. amount of comorbidities and E. diabetes.

F. Global weighted network after communities' detection. Biomarkers with COVID-19 related mortality belong to communities 4 and 5 (labeled). The size of the bubble represents the connectivity of each metabolite.

G. Heatmap of potential biomarkers and first neighbors in patients. Outcome (survivors/non-survivors) and mask type is indicated. Data were log-transformed.